TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Angioarchitecture of Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age above 18 years~2. HCC suitable for partial hepatectomy~3. Child-Pugh A or B cirrhosis~4. Eastern Cooperative Oncology Group performance score 0 or 1~5. Barcelona clinic liver cancer (BCLC) staging A or B~6. HCC diagnosed by typical enhancement patterns on cross sectional imaging or histology~7. Massive expansive tumor morphology with measurable lesion on CT (characterized by well-defined spherical or globular configuration, with or without tumor capsule or satellite lesions)~Exclusion Criteria:~1. Previous treatment with liver resection, ablation, chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy),~2. Evidence of tumor invasion of portal vein or hepatic vein~3. History of acute tumor rupture presenting with hemo-peritoneum~4. Infiltrative tumor morphology (characterized by ill- defined tumor margin and amorphous configuration) or diffuse tumor morphology (characterized by large number of small nodules)~5. Serum creatinine level \> 150umol/L

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tumor <=3cm (Type: OTHER): Embolization with particulate or liquid embolic agent
- Tumor >3cm to 7cm (Type: OTHER): Embolization with particulate or liquid embolic agent
- Tumor > 7cm (Type: OTHER): Embolization with particulate or liquid embolic agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 2 to \<18 years of age; Subjects 2 to \<12 years of age will be permitted to enroll in this study only after a Pfizer sponsored pharmacokinetic study confirms the proposed dosage corresponding to this age group is appropriate.~* Patients with confirmed Candida infection of the blood, body tissues, or the esophagus.~* Patient's doctor feels voriconazole is an appropriate choice of therapy.~Exclusion Criteria:~* A known allergy to voriconazole or to azole to antifungal drugs.~* Females who are pregnant, lactating (breast feeding) or planning a pregnancy during the course of the study, or who are of childbearing potential and not using highly effective method of birth control.~* A patient who is receiving treatment with a drug know to interfere with the heart's electrical system (QTc prolongation).~* A patient who is receiving treatment with a drug that is not permitted to be used with voriconazole.~* For primary therapy: a patient who has received more than 48 hours of antifungal therapy for the current episode of Candida infection.~* A patient with significant underlying liver disease at the time of enrollment in the study.~* A patient with significant renal disease (CrCl \< 50 ml/min) at the time of enrollment in the study.~* A patient with a high likelihood of death within 72 hours of study enrollment due to factors unrelated to Candida infection.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Active voriconazole (Type: EXPERIMENTAL): All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients must have diagnosis of breast cancer or non small cell lung cancer~* Patients must have evaluable disease~* Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study.~* Patients must have given signed, informed consent prior to registration on study.~Exclusion Criteria:~* Patients must not be pregnant and/or lactating.~* Patients must not be receiving any other investigational agents.~* No prior exposure to vinorelbine or other VEGF inhibitors as treatment for metastatic disease~* Patients must not have received prior therapy (including radiation, surgery, and/or chemotherapy) within 30 days~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or vinorelbine.~* Patients cannot have received more than 2 prior chemotherapy regimens for lung cancer or 3 prior chemotherapy regimens for breast cancer. This criterion can be discussed further with the study doctor.~* Must not have uncontrolled illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmic, psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib + Vinorelbine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving chemoradiation therapy~* Documented ovarian function~* Require menstrual suppression with GnRHa during chemoradiation therapy~* Patients at the University of Kentucky, Norton Healthcare or Cincinnati Children's Hospital Medical Center~Exclusion Criteria:~* Under 8 years of age and older than 19 years of age~* Male~* Unable to provide consent or assent

- Gender: FEMALE
- Minimum Age: 8 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Cases (Type: OTHER): Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
- Controls (Type: OTHER): Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18 to 65 years of age with hypertension, treated with three or more anti-hypertensive drugs, one being a diuretic, and~* having a systolic blood pressure \>150 mmHg in the clinic and daytime average \>150 mmHg on ambulatory blood pressure monitoring~Exclusion Criteria:~* Medical history of secondary cause of hypertension, severe obesity (BMI \>35), severe psychiatric disorders, cancer in the last 5 years other than nonmelanoma skin cell cancers, herpes zoster or cytomegalovirus that resolved less than 2 months before~* Inability to return for abatacept treatment and follow-up for 24 weeks.~* Inability to understand or complete study-related assessments.~* Current abuse of drugs or alcohol.~* Receipt of any live vaccines within 3 months of the anticipated first dose of study medication.~* Evidence of active or latent bacterial or viral infections at the time of potential enrollment, including human immunodeficiency virus (HIV)~* Risk for tuberculosis~* Abnormal laboratory values including positive hepatitis B surface antigen, hemoglobin \< 8.5 g/dL, white blood cell count \< 3000/mm3, platelets \< 100,000/mm3, creatinine \> 2.5 times the upper limit of normal (ULN), alanine aminotransferase or aspartate aminotransferase \> 2 times the ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- abatacept (Type: ACTIVE_COMPARATOR): Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those \>100 kg will receive 1000 mg abatacept by intravenous infusion at 0 \[randomization\], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
- placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 \[randomization\], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Arterial Cannulation With Ultrasound

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled to undergo major elective or urgent (not requiring intervention in \<24 hours) non-cardiac surgery under general anaesthesia and/or neuraxial anaesthesia, expected to take \>120 minutes from induction of anaesthesia~2. Requiring overnight hospital stay.~Exclusion Criteria:~1. Anatomical deformity~2. Unable to consent~3. Cannulation attempt within 24 hours~4. Overlying infection

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ultrasound guided arterial cannulation (Type: EXPERIMENTAL): Anaesthetist will use real-time ultrasound guidance to guide arterial cannulation
- Palpation guided arterial cannulation (Type: ACTIVE_COMPARATOR): Anaesthetist will use palpation (standard-of-care) technique to guide arterial cannulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feeding Study in VLBW Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically and metabolically stable~* Birth weight 700 g to less than or equal to 1,250 g~* Appropriate birth weight for gestational age~* 24 0/7 to 32 0/7 weeks' gestational age at birth~* Exclusively fed human milk~* Signed informed consent and authorization to use and/or disclose PHI~Exclusion Criteria:~* Metabolic or chronic disease~* 5-minute Apgar score \<4~* Major surgery~* Ventilator dependent~* Fluid restriction~* Grade III or IV intraventricular hemorrhage (IVH)

- Gender: ALL
- Minimum Age: 168 Days
- Maximum Age: 224 Days
- Healthy Volunteers: f

Study Arms:
- Commercial Liquid Human Milk Fortifier (Type: ACTIVE_COMPARATOR): Liquid human milk fortifier to be added to human milk
- Liquid Human Milk Fortifier - Standard Protein (Type: EXPERIMENTAL): Liquid human milk fortifier to be added to human milk
- Liquid Human Milk Fortifier - High Protein (Type: EXPERIMENTAL): Liquid human milk fortifier to be added to human milk

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sevoflurane in Chronic Obstructive Pulmonary Disease Exacerbation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* COPD exacerbation~* Invasive mechanical ventilation and sedation for a planned duration of at least 24 hours~* Consent~* Age ≥ 18 years~* Affiliation or beneficiary of a social security scheme~Exclusion Criteria :~* Contraindication to the administration of sevoflurane (personal or family history of malignant hyperthermia, allergy or halogenated anesthetic accident, chronic myopathy, halogenated toxic hepatitis, uncontrolled intracranial hypertension, unexplained leukocytosis after anesthesia with a halogenated agent)~* Contraindication to the administration of propofol (known hypersensitivity to propofol, soy, peanut or any of the excipients of the emulsion, antecedent of Propofol Related Infusion Syndrome)~* Refusal of consent~* Guardianship~* Age \< 18 years~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevoflurane group (Type: EXPERIMENTAL): None
- Propofol group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. All children greater than 6 months of age and less than 18 years of age with newly-diagnosed previously untreated or previously diagnosed JMML, which has reoccurred after treatment with chemotherapy, stem cell transplantation, and/or cis-retinoic acid.~2. A diagnosis of JMML is confirmed only if the following criteria for JMML are met: a) ALL of the following: Absence of t(9;22) or BCR-ABL by PCR or FISH; Absolute monocyte count \>1000 (1 X 109/µL); \<20% bone marrow blasts; b) At least 2 of the following: Elevated Hb F hemoglobin; Myeloid precursors in peripheral blood; WBC \>10,000 (10 X 109/µL); GM-CSF hypersensitivity in methylcellulose culture of bone marrow progenitors cells.~3. Adequate hepatic function (bilirubin equal or less than 2.0 mg/dl; ALT equal or less than 3x normal)~4. Adequate renal function (serum creatinine equal or less than 2 x normal)~5. Performance Status: Have a Karnofsky score \>50.~6. Written, informed consent according to institution guidelines.~Exclusion Criteria:~1. Pregnant or lactating.~2. Receiving any other chemotherapy. Patients must have been off chemotherapy for at least 2 weeks and must have recovered from acute toxicity of all previous therapy prior to enrollment.~3. Febrile neutropenia at study entry.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): 0.8 mg/kg subcutaneously weekly for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects meeting all of the following criteria will be considered for admission to the study:~1. Male or female subject aged between 8 and 23 years of age; only patients up to the age of 23 will be studied at Childrens Hospital Los Angeles~2. Electrophoretic diagnosis of sickle cell disease;~3. Sudden onset of acute pain involving \>=1 sites typical of vaso-occlusive crisis (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest, abdomen, or back that can not be explained by other complications of sickle cell disease or by a cause other than sickle cell disease.);~4. Severe pain requiring parenteral analgesics and hospitalization.~5. Informed consent obtained from a legal representative or from subjects 18 years of age or older before enrollment;~6. Being willing and able to be followed for at least 30 days for evaluation.~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~1. Clinically significant bleeding;~2. Current drug abuse or participation in methadone program;~3. Episode of pain requiring hospitalization within 2 weeks prior to current admission;~4. Other complications of sickle cell disease including cerebrovascular accident, pulmonary hypertension, or seizure;~5. Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding;~6. Blood pressure less than 25th percentile for the subject's age and sex on admission or at the time of screening;~7. Methemoglobinemia \>3%;~8. Anemia with hemoglobin level less than 6 g/dL;~9. Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;~10. History of allergy to nitrites or allergy to other substances characterized by dyspnea and cyanosis;~11. Treatment with allopurinol, a medication that could interfere with nitrite metabolism, within the past 30 days before screening;~12. Treatment with any investigational drug within the past 30 days;~13. Significant acute or chronic concomitant diseases (including renal, hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 6 months;~14. Any subject judged by the clinical investigator or study manager to be inappropriate for the study.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- No drug (Type: NO_INTERVENTION): No study drug administered
- Sodium nitrite injection, USP (Type: EXPERIMENTAL): Administration if sodium nitrite injection, USP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study of the Biomechanical Properties of Large Allografts

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients that require retrieval of a previously implanted large allograft.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retrieved Allograft (Type: None): Patients that require the retrieval of a bone allograft (transplant).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Diagnostic Lumbar Puncture in Neurology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled for LP through Neurology's LP clinic~* 18 years of age or older~* Able to understand the description of procedure and provide informed consent~Exclusion Criteria:~* Any contraindications to doing a standard lumbar puncture; which typically includes risk of bleeding from effects of anticoagulants or bleeding disorders or an infection at the potential site of entry in the back. This includes subjects with spinal cord stimulators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Landmark-based lumbar puncture (Type: ACTIVE_COMPARATOR): Landmark-based LP
- Ultrasound-guided lumbar puncture (Type: ACTIVE_COMPARATOR): Ultrasound-guided LP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy